Bessemer Group’s VanEck Biotech ETF BBH Stock Holding History

Bessemer Group’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-180	Closed	-$21K	–	1484
2014 Q4	$21K	Buy	+180	New	+$20.3K	﹤0.01%	1101
2014 Q2	–	Sell	-74	Closed	-$7K	–	1403
2014 Q1	$7K	Buy	+74	New	+$7.19K	﹤0.01%	1119

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Bessemer Group's BBH Position: Q1 2015 in Review

Bessemer Group sold out of VanEck Biotech ETF (BBH) in Q1 2015, closing a stake of 180 shares — an estimated $21K sold.

Bessemer Group first reported a position in BBH in Q1 2014 and held it in 2 quarters. The position peaked at $21K in Q4 2014. 78 funds tracked by Wall St. Rank hold BBH as of Q1 2015.

Bessemer Group reported no remaining VanEck Biotech ETF position as of Q1 2015 after selling out during the quarter.
Bessemer Group sold 180 VanEck Biotech ETF shares in Q1 2015, an estimated $21K.
Bessemer Group first reported a position in VanEck Biotech ETF in Q1 2014 and held it in 2 quarters.
Bessemer Group's VanEck Biotech ETF position peaked at $21K in Q4 2014.
78 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2015.

Based on Bessemer Group's 13F filing for Q1 2015, filed 14 May 2015.